New drug to stop 'Ozempic butt' muscle loss side effect of obesity jabs
Pusulam brief
Researchers are developing a new drug to prevent muscle loss, a side effect of obesity medications (GLP-1 agonists). Studies show that one-third of weight loss from these jabs comes from muscle tissue, and scientists are working on solutions to address this issue.
While GLP-1 agonists help millions lose weight, muscle loss can cause long-term health complications. Solving this problem will make obesity treatment safer and more effective for patients worldwide.
A third of the weight loss from obesity jabs can come from muscle, say experts.
Why good news?
Scientific efforts to reduce side effects while maintaining treatment effectiveness represent progress toward safer obesity management. Solving the muscle loss problem will significantly improve treatment quality and patient outcomes.
Why it matters?
While GLP-1 agonists help millions lose weight, muscle loss can cause long-term health complications. Solving this problem will make obesity treatment safer and more effective for patients worldwide.
Reading rights
We do not have rights to republish the full article text from this source. Pusulam shows the open RSS context, source link, and its own analysis; use the source link for the full story.
Do you think this development will have a positive impact?
Pusulam AI
Chat with this story
Ask for a summary, why it matters, or missing context.
Source
For this source, we show summary, analysis, and open RSS context only. Read the full story at the source.
Read at source →